Back to Browse Journals » International Journal of General Medicine » Volume 4

Amino acid management of Parkinson’s disease: a case study

Authors Marty Hinz, Alvin Stein, Thomas Uncini

Published Date February 2011 Volume 2011:4 Pages 165—174

DOI http://dx.doi.org/10.2147/IJGM.S16621

Published 28 February 2011

Marty Hinz1, Alvin Stein2, Thomas Uncini3
1
Clinical Research, NeuroResearch Clinics, Inc., Cape Coral, FL, USA; 2Stein Orthopedic Associates, Plantation, FL, USA; 3DBS Labs, Duluth, MN, USA

Abstract: An extensive list of side effects and problems are associated with the administration of L-dopa (L-3, 4-dihydroxyphenylalanine) during treatment of Parkinson’s disease. These problems can preclude achieving an optimal response with L-dopa treatment.
Purpose: To present a case study outlining a novel approach for the treatment of Parkinson’s disease that allows for management of problems associated with L-dopa administration and discusses the scientific basis for this treatment.
Patients and methods: The case study was selected from a database containing 254 Parkinson’s patients treated in developing and refining this novel approach to its current state. The spectrum of patients comprising this database range from newly diagnosed, with no previous treatment, to those who were diagnosed more than 20 years before and had virtually exhausted all medical treatment options. Parkinson’s disease is associated with depletion of tyrosine hydroxylase, dopamine, serotonin, and norepinephrine. Exacerbating this is the fact that administration of L-dopa may deplete L-tyrosine, L-tryptophan, 5-hydroxytryptophan (5-HTP), serotonin, and sulfur amino acids. The properly balanced administration of L-dopa in conjunction with 5-HTP, L-tyrosine, L-cysteine, and cofactors under the guidance of organic cation transporter functional status determination (herein referred to as “OCT assay interpretation”) of urinary serotonin and dopamine, is at the heart of this novel treatment protocol.
Results: When 5-HTP and L-dopa are administered in proper balance along with L-tyrosine, L-cysteine, and cofactors under the guidance of OCT assay interpretation, the long list of problems that can interfere with optimum administration of L-dopa becomes controllable and manageable or does not occur at all. Patient treatment then becomes more effective by allowing the implementation of the optimal dosing levels of L-dopa needed for the relief of symptoms without the dosing value barriers imposed by side effects and adverse reactions seen in the past.

Keywords: Parkinson’s, Parkinsonism, Parkinson’s disease, L-dopa, 5-HTP

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

Management of L-dopa overdose in the competitive inhibition state

Hinz M, Stein A, Cole T

Drug, Healthcare and Patient Safety 2014, 6:93-99

Published Date: 22 July 2014

5-HTP efficacy and contraindications

Hinz M, Stein A, Uncini T

Neuropsychiatric Disease and Treatment 2012, 8:323-328

Published Date: 19 July 2012

Relative nutritional deficiencies associated with centrally acting monoamines

Hinz M, Stein A, Uncini T

International Journal of General Medicine 2012, 5:413-430

Published Date: 8 May 2012

The discrediting of the monoamine hypothesis

Hinz M, Stein A, Uncini T

International Journal of General Medicine 2012, 5:135-142

Published Date: 14 February 2012

Monoamine depletion by reuptake inhibitors

Hinz M, Stein A, Uncini T

Drug, Healthcare and Patient Safety 2011, 3:69-77

Published Date: 20 October 2011

APRESS: apical regulatory super system, serotonin, and dopamine interaction

Hinz M, Stein A, Uncini T

Neuropsychiatric Disease and Treatment 2011, 7:457-463

Published Date: 5 August 2011

Urinary neurotransmitter testing: considerations of spot baseline norepinephrine and epinephrine

Marty Hinz, Alvin Stein, Thomas Uncini

Research and Reports in Urology 2011, 3:19-24

Published Date: 4 February 2011

Treatment of attention deficit hyperactivity disorder with monoamine amino acid precursors and organic cation transporter assay interpretation

Marty Hinz, Alvin Stein, Robert Neff, et al

Neuropsychiatric Disease and Treatment 2011, 7:31-38

Published Date: 26 January 2011

Amino acid-responsive Crohn's disease: a case study

Alvin Stein, Marty Hinz, Thomas Uncini

Clinical and Experimental Gastroenterology 2010, 3:171-177

Published Date: 6 December 2010

A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive pole

Marty Hinz, Alvin Stein, Thomas Uncini

Neuropsychiatric Disease and Treatment 2010, 6:741-747

Published Date: 9 November 2010

Neurotransmitter testing of the urine: a comprehensive analysis

Marty Hinz, Alvin Stein, George Trachte, et al

Research and Reports in Urology 2010, 2:177-183

Published Date: 7 October 2010

The dual-gate lumen model of renal monoamine transport

Marty Hinz, Alvin Stein, Thomas Uncini

Neuropsychiatric Disease and Treatment 2010, 6:387-392

Published Date: 5 July 2010

Readers of this article also read:

Newer agents in antiplatelet therapy: a review

Yeung J, Holinstat M

Journal of Blood Medicine 2012, 3:33-42

Published Date: 25 June 2012

Benefit of intravenous antibiotic therapy in patients referred for treatment of neurologic Lyme disease

Stricker RB, DeLong AK, Green CL, Savely VR, Chamallas SN, Johnson L

International Journal of General Medicine 2011, 4:639-646

Published Date: 6 September 2011

Radio electric asymmetric brain stimulation in the treatment of behavioral and psychiatric symptoms in Alzheimer disease

Mannu P, Rinaldi S, Fontani V, Castagna A

Clinical Interventions in Aging 2011, 6:207-211

Published Date: 26 July 2011

Update on rabies

Alan C Jackson

Research and Reports in Tropical Medicine 2011, 2:31-43

Published Date: 2 February 2011

Amino acid-responsive Crohn's disease: a case study

Alvin Stein, Marty Hinz, Thomas Uncini

Clinical and Experimental Gastroenterology 2010, 3:171-177

Published Date: 6 December 2010

Neurotransmitter testing of the urine: a comprehensive analysis

Marty Hinz, Alvin Stein, George Trachte, et al

Research and Reports in Urology 2010, 2:177-183

Published Date: 7 October 2010

Effects of selective serotonin reuptake inhibitors on motor neuron survival

Lily B Anderson, Phaedra B Anderson, Thea B Anderson, Amy Bishop, et al.

International Journal of General Medicine 2009, 2:109-115

Published Date: 28 May 2009

Local anesthetic failure associated with inflammation: verification of the acidosis mechanism and the hypothetic participation of inflammatory peroxynitrite

Takahiro Ueno, Hironori Tsuchiya, Maki Mizogami, Ko Takakura

Journal of Inflammation Research 2008, 1:41-48

Published Date: 13 November 2008